Molluscum Contagiosum Clinical Trial
Official title:
The Effectiveness of Oral Acyclovir in the Treatment of Molluscum Contagiosum in Children
The investigators will study the effectiveness of acyclovir in the treatment of molluscum contagiosum in assiut university hospital - dermatological out patient clinic the treatment group will receive acyclovir 200 mg 5 times per day the controlled group will receive local KOH solution
Study population:
Site of the study: The outpatient dermatological clinic in Assiut university hospital.
Participants: children (2 -16) years' old attending dermatological clinic in Assiut
university hospital and their parents.
Methodology in details:
1. We will use the social media as " Facebook" to invite patient to visit the clinic and
follow up them due to the protective measures of covid 19.
2. Diagnosis of the patient with molluscum contagiosum according to the clinical picture
3. Collecting data including personal and clinical data through interviewing the patient
and his or her parents
4. Pictures of the lesions will be taken before and after treatment after patient consent.
5. We will Randomly assigning the patient to either treatment group or controlled group
according to simple random table
6. Prescribing the treatment according to the patient group
7. Follow up of the patient after 1 weak and each week according to the response to
treatment or presence of complication
Inclusion criteria:
Children (5 -15) years old with Molluscum contagiosum.
Exclusion criteria:
1. Molluscum contagiosum with Inflamed spot
2. Known immune compromised children
3. Molluscum lesion in the eye lid.
4. Children with renal impairment.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03017846 -
Safety and Efficacy of Topical Cantharidin for the Treatment of Molluscum Contagiosum, Phase 2
|
Phase 2 | |
| Recruiting |
NCT05937672 -
Cold Atmospheric Plasma Device Extension Study
|
Phase 3 | |
| Completed |
NCT04535531 -
A Phase 3 Molluscum Contagiosum Efficacy and Safety Study
|
Phase 3 | |
| Completed |
NCT02902822 -
Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo
|
N/A | |
| Completed |
NCT05897112 -
Comparative Efficacy of 10% Potassium Hydroxide Solution Versus Cryotherapy in Molluscum Contagiosum
|
Phase 1 | |
| Withdrawn |
NCT05536882 -
MC RCT - BPO vs Adapalene
|
Phase 3 | |
| Completed |
NCT03377790 -
Cantharidin Application in Molluscum Patients-1
|
Phase 3 | |
| Completed |
NCT01348386 -
Efficacy and Tolerance of Potassium Hydroxide (10% and 15%) in Molluscum Contagiosum
|
Phase 2/Phase 3 | |
| Completed |
NCT05634460 -
Comparison of 5% Potassium Hydroxide With 10% Potassium Hydroxide Solution in Treatment of Molluscum Contagiosum
|
Phase 1 | |
| Completed |
NCT03186378 -
Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum.
|
Phase 2 | |
| Completed |
NCT03927716 -
A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1)
|
Phase 3 | |
| Completed |
NCT03927703 -
A Phase 3 Efficacy & Safety of SB206 & Vehicle Gel for the Treatment of MC
|
Phase 3 | |
| Completed |
NCT02665260 -
Safety and Efficacy Study of Topical Cantharidin for the Treatment of Molluscum Contagiosum
|
Phase 2 | |
| Completed |
NCT03436615 -
A Study to Evaluate the Safety and Efficacy of SB206 in Subjects With Molluscum Contagiosum
|
Phase 2 | |
| Recruiting |
NCT02759900 -
Using a Cold Atmospheric Plasma Device to Treat Skin Disorders
|
N/A | |
| Completed |
NCT05680181 -
Study of a Cohort of Children With Molluscum Contagiosum (MC) Treated With a 5% Solution of Potassium Hydroxide (Molutrex®) Applied Locally to the Skin
|
||
| Completed |
NCT03077750 -
A Study of VBP-245 in Pediatric Patients With Molluscum Contagiosum
|
Phase 2 | |
| Terminated |
NCT02024581 -
A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of Molluscum Contagiosum
|
Phase 2 | |
| Completed |
NCT03377803 -
Cantharidin Application in Molluscum Patients
|
Phase 3 | |
| Withdrawn |
NCT03336372 -
Picato for the Treatment of Molluscum Contagiosum in Immunocompromised Patients
|
Early Phase 1 |